• Je něco špatně v tomto záznamu ?

Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics

DT. Keough, D. Rejman, R. Pohl, E. Zborníková, D. Hocková, T. Croll, MD. Edstein, GW. Birrell, M. Chavchich, LMJ. Naesens, GK. Pierens, IM. Brereton, LW. Guddat,

. 2018 ; 13 (1) : 82-90. [pub] 20171205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024474

Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the foremost causative agents of malaria. Due to the development of resistance to current antimalarial medications, new drugs for this parasitic disease need to be discovered. The activity of hypoxanthine-guanine-[xanthine]-phosphoribosyltransferase, HG[X]PRT, is reported to be essential for the growth of both of these parasites, making it an excellent target for antimalarial drug discovery. Here, we have used rational structure-based methods to design an inhibitor, [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine, of PvHGPRT and PfHGXPRT that has Ki values of 8 and 7 nM, respectively, for these two enzymes. The crystal structure of PvHGPRT in complex with this compound has been determined to 2.85 Å resolution. The corresponding complex with human HGPRT was also obtained to allow a direct comparison of the binding modes of this compound with the two enzymes. The tetra-(ethyl l-phenylalanine) tetraamide prodrug of this compound was synthesized, and it has an IC50 of 11.7 ± 3.2 μM against Pf lines grown in culture and a CC50 in human A549 cell lines of 102 ± 11 μM, thus giving it a ∼10-fold selectivity index.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024474
003      
CZ-PrNML
005      
20180713094008.0
007      
ta
008      
180709s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acschembio.7b00916 $2 doi
035    __
$a (PubMed)29161011
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Keough, Dianne T $u School of Chemistry and Molecular Biosciences, The University of Queensland , Brisbane 4072, Australia.
245    10
$a Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics / $c DT. Keough, D. Rejman, R. Pohl, E. Zborníková, D. Hocková, T. Croll, MD. Edstein, GW. Birrell, M. Chavchich, LMJ. Naesens, GK. Pierens, IM. Brereton, LW. Guddat,
520    9_
$a Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the foremost causative agents of malaria. Due to the development of resistance to current antimalarial medications, new drugs for this parasitic disease need to be discovered. The activity of hypoxanthine-guanine-[xanthine]-phosphoribosyltransferase, HG[X]PRT, is reported to be essential for the growth of both of these parasites, making it an excellent target for antimalarial drug discovery. Here, we have used rational structure-based methods to design an inhibitor, [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine, of PvHGPRT and PfHGXPRT that has Ki values of 8 and 7 nM, respectively, for these two enzymes. The crystal structure of PvHGPRT in complex with this compound has been determined to 2.85 Å resolution. The corresponding complex with human HGPRT was also obtained to allow a direct comparison of the binding modes of this compound with the two enzymes. The tetra-(ethyl l-phenylalanine) tetraamide prodrug of this compound was synthesized, and it has an IC50 of 11.7 ± 3.2 μM against Pf lines grown in culture and a CC50 in human A549 cell lines of 102 ± 11 μM, thus giving it a ∼10-fold selectivity index.
650    _2
$a antimalarika $x chemie $x farmakologie $7 D000962
650    _2
$a katalytická doména $7 D020134
650    _2
$a techniky syntetické chemie $7 D060326
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a bisfosfonáty $x chemie $x farmakologie $7 D004164
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a proteiny z Escherichia coli $x chemie $7 D029968
650    _2
$a lidé $7 D006801
650    _2
$a hypoxanthinfosforibosyltransferasa $x antagonisté a inhibitory $x chemie $x metabolismus $7 D007041
650    _2
$a molekulární modely $7 D008958
650    _2
$a pentosyltransferasy $x antagonisté a inhibitory $x chemie $x metabolismus $7 D010430
650    _2
$a Plasmodium vivax $x enzymologie $7 D010966
650    _2
$a konformace proteinů $7 D011487
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rejman, Dominik $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences , CZ-166 10 Prague 6, Czech Republic.
700    1_
$a Pohl, Radek $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences , CZ-166 10 Prague 6, Czech Republic.
700    1_
$a Zborníková, Eva $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences , CZ-166 10 Prague 6, Czech Republic.
700    1_
$a Hocková, Dana $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences , CZ-166 10 Prague 6, Czech Republic.
700    1_
$a Croll, Tristan $u Institute of Health and Biomedical Innovation, Queensland University of Technology , 2 George St, Brisbane 4000, Australia.
700    1_
$a Edstein, Michael D $u Department of Drug Evaluation, Australian Army Malaria Institute , Enoggera 4051, Australia.
700    1_
$a Birrell, Geoff W $u Department of Drug Evaluation, Australian Army Malaria Institute , Enoggera 4051, Australia.
700    1_
$a Chavchich, Marina $u Department of Drug Evaluation, Australian Army Malaria Institute , Enoggera 4051, Australia.
700    1_
$a Naesens, Lieve M J $u Rega Institute for Medical Research, Katholique University , Minderbroedersstraat 10, B-3000 Leuven, Belgium.
700    1_
$a Pierens, Gregory K $u Centre for Advanced Imaging, The University of Queensland , St Lucia 4072, Australia.
700    1_
$a Brereton, Ian M $u Centre for Advanced Imaging, The University of Queensland , St Lucia 4072, Australia.
700    1_
$a Guddat, Luke W $u School of Chemistry and Molecular Biosciences, The University of Queensland , Brisbane 4072, Australia.
773    0_
$w MED00179502 $t ACS chemical biology $x 1554-8937 $g Roč. 13, č. 1 (2018), s. 82-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29161011 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180713094301 $b ABA008
999    __
$a ok $b bmc $g 1316605 $s 1021395
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 13 $c 1 $d 82-90 $e 20171205 $i 1554-8937 $m ACS chemical biology $n ACS Chem Biol $x MED00179502
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace